Status:
COMPLETED
A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This 7 cohort study will evaluate the efficacy and safety of combination treatment with an HCV nucleoside polymerase inhibitor(RO5024048)and an HCV protease inhibitor(RO5190591/ITMN-191/danoprevir) in...
Eligibility Criteria
Inclusion
- adult patients, 18-65 years of age;
- chronic hepatitis C, genotype 1.
Exclusion
- decompensated liver disease, or impaired liver function;
- presence or history of non-hepatitis C chronic liver disease;
- HBsAg or HIV infection;
- history of cancer within 5 years, other than localized or in situ cancer of the skin.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00801255
Start Date
November 1 2008
End Date
March 1 2010
Last Update
November 2 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Adelaide, Australia, SA 5000
2
Heidelberg, Australia, 3084
3
Melbourne, Australia, 3181
4
Christchurch, New Zealand, 8011